IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Trial record 1 of 1 for:
NCT01654341
Multi-Modal Intervention In Frail And Prefrail Older People With Type 2 Diabetes (MID-Frail)
This study is ongoing, but not recruiting participants.
Sponsor:
Hospital Universitario Getafe
Collaborators:
Cardiff University
Igen Biotech SL
University Hospital, Bordeaux
Hexabio Sarl
Second University of Naples
University Hospital, Toulouse
University of Ulm
University Ghent
University of Castilla-La Mancha
Univerzita Karlova v Praze
Niche Science & Technology Ltd
Catholic University of the Sacred Heart
Vrije Universiteit Brussel
Diabetes Frail Ltd
Information provided by (Responsible Party):
Hospital Universitario Getafe
ClinicalTrials.gov Identifier:
NCT01654341
First received: July 27, 2012
Last updated: March 22, 2016
Last verified: February 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The MID-Frail STUDY project focuses on the use of interventions designed to improve functional status and enhance quality of life (rather than traditional treatments such as glucose- and blood pressure- lowering) by acting on the mechanisms involved in producing frailty and its progression to adverse outcomes.
| Condition | Intervention |
|---|---|
| Type 2 Diabetes Mellitus | Behavioral: Exercise, dietary and educational program |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | A RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFECTIVENESS OF A MULTI-MODAL INTERVENTION IN FRAIL AND PREFRAIL OLDER PEOPLE WITH TYPE 2 DIABETES ON FRAILTY AND QUALITY OF LIFE: THE MID-Frail STUDY |
Further study details as provided by Hospital Universitario Getafe:
Primary Outcome Measures:
- Changes in summary ordinal score on the Short Physical Performance Battery test [ Time Frame: 2 years ]The Short Physical Performance Battery (SPPB) is a simple test to measure lower extremity function using tasks that mimic daily activities. The SPPB examines 3 areas of lower extremity function; static balance, gait speed, and getting in and out of a chair. These areas represent essential tasks important for independent living and are thus an important outcome measure for patients with cardiovascular and pulmonary disease.
Secondary Outcome Measures:
- Lawton Instrumental Activity of Daily Living (IADL) scale [ Time Frame: 2 years ]
- Barthel index of activities of daily living [ Time Frame: 2 years ]
- Euro-Quality of Life (QoL) index [ Time Frame: 2 years ]
- Economic costs/healthcare expenditure due to diabetes and its impact on disability and quality of life, [ Time Frame: 2 years ]Economic costs/healthcare expenditure due to diabetes and its impact on disability and quality of life, using an economic model embracing the direct health-related costs (in-patient, out-patient, pharmaceutical, etc), formal care costs (home care, respite care, day centers, etc) and the informal care costs (carer).
- Symptomatic hypoglycaemia [ Time Frame: 2 years ]Episodes of symptomatic hypoglycaemia (i.e., a recorded blood sugar less than 4 mmol/L, or symptoms or signs attributed to low blood sugar and responding to appropriate treatment)
- Hospital admissions [ Time Frame: 2 years ]Episodes of hospital admission (i.e., any admission involving an overnight stay)
- Episodes of permanent institutionalization [ Time Frame: 2 years ]Episodes of permanent institutionalization (i.e., permanent move to any care setting other than the patient's own home, where paid staff are available to provide care if needed at any time during the day or night).
- Caregiver Strain Index [ Time Frame: 2 years ]Burden of the carer, as assessed by the modified Caregiver Strain Index
- Mortality [ Time Frame: 2 years ]
| Enrollment: | 986 |
| Study Start Date: | December 2013 |
| Estimated Study Completion Date: | March 2017 |
| Estimated Primary Completion Date: | March 2017 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: Usual Care Group
Subjects undergo usual standard of care
|
|
|
Experimental: Intervention Group
Intervention with exercise, dietary and educational programs
|
Behavioral: Exercise, dietary and educational program |
Detailed Description:
Detailed Description: Subjects enrolled in the main study will also be invited to join the following sub-studies:
GENEFRAIL: this sub-study aims to determine the polymorphisms of several genes associated to frailty, in order to establish its predictive value for developing disability and response to treatment as well METABOFRAIL: this sub-study aims to investigate the metabolomic profile of frail and pre-frail patients. SARTRAIN: the combination of the assessment tools used in SARTRAIN (ARFI US, MRI, posturographic measurements) will provide a comprehensive study of the structural and functional characteristics of muscle and adjacent tissues and their change with time and the intervention. MID- POW: this sub-study aims to investigate changes in muscle power.
The project also include an randomized controlled ancillary study: SENSOLE for which the aim is to investigate the potential effects of vibrating insoles device on gait and posture.
Eligibility| Ages Eligible for Study: | 70 Years and older (Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Participant is willing and able to give written informed consent for participation in the study.
- Subjects aged 70 years or older, with a diagnosis of type 2 diabetes mellitus for at least 2 years.
- Require to fulfill Fried ́s criteria for frail or pre-frail individuals.
Exclusion criteria:
- Barthel score lower than 60 points.
- Inability to carry out SPPB test (total score=0).
- Mini Mental State Examination score less than 20 points.
- Subjects unwilling or unable to consent or unable to participate safely in intervention program.
- Previous history of myocardial infarction within 6 months, unstable angina or congestive heart failure in III-IV NYHA stage.
- Clinically instable patients in the clinical judgment of the investigator.
- Terminal illness (life expectancy < 6 months).
- Any other condition that, in the clinical judgment of the investigator, means that it would not in the patient's best interests to enter the study.
- Current participation in clinical trial or any other investigational study.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01654341
Please refer to this study by its ClinicalTrials.gov identifier: NCT01654341
Locations
| Spain | |
| Hospital Universitario de Getafe | |
| Madrid, Getafe, Spain, 28905 | |
Sponsors and Collaborators
Hospital Universitario Getafe
Cardiff University
Igen Biotech SL
University Hospital, Bordeaux
Hexabio Sarl
Second University of Naples
University Hospital, Toulouse
University of Ulm
University Ghent
University of Castilla-La Mancha
Univerzita Karlova v Praze
Niche Science & Technology Ltd
Catholic University of the Sacred Heart
Vrije Universiteit Brussel
Diabetes Frail Ltd
Investigators
| Principal Investigator: | Leocadio Rodríguez Mañas, MD | Hospital Universitario de Getafe |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Hospital Universitario Getafe |
| ClinicalTrials.gov Identifier: | NCT01654341 History of Changes |
| Obsolete Identifiers: | NCT01541787 |
| Other Study ID Numbers: |
MID-Frail 278803-2 ( Other Identifier: European Commission: CORDIS: Seventh Framework Programme (FP7) ) |
| Study First Received: | July 27, 2012 |
| Last Updated: | March 22, 2016 |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on July 28, 2017